| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Dec 3, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $36.45 | $36,450.00 | -100% | |
| Dec 3, 2018 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 1,178 | $90.00 | $106,019.65 | -37.7% | |
| Dec 3, 2018 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO, President, Secretary | Buy | 1,000 | $5.17 | $5,165.00 | +15.6% | |
| Dec 3, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 1,089 | $22.00 | $23,958.00 | -2.0% | |
| Dec 3, 2018 | BCRX Biocryst Pharmaceuticals Inc | Stonehouse Jon P80 | President &CEO | Sell | 80,000 | $9.12 | $729,600.00 | -9.9% | |
| Dec 3, 2018 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Buy | 500 | $5.20 | $2,599.95 | +50.0% | |
| Dec 3, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 16,630 | $22.44 | $373,177.20 | -8.3% | |
| Dec 3, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 10,000 | $22.40 | $224,001.00 | -11.3% | |
| Dec 3, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $5.07 | $926,796.00 | -1.4% | |
| Nov 30, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob47 | SVP Corp Admin Center | Sell | 13,980 | $21.50 | $300,513.41 | -24.2% | |
| Nov 30, 2018 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Buy | 450 | $5.20 | $2,339.55 | +90.0% | |
| Nov 30, 2018 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Buy | 500 | $5.00 | $2,500.00 | +100.0% | |
| Nov 30, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 17,042 | $17.79 | $303,173.77 | -4.8% | |
| Nov 30, 2018 | BCRX Biocryst Pharmaceuticals Inc | Barnes Alane P70 | Senior VP, Chief Legal Officer | Sell | 44,290 | $9.07 | $401,710.30 | -36.2% | |
| Nov 30, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 23,306 | $17.81 | $414,998.29 | -9.7% | |
| Nov 30, 2018 | BTAI Bioxcel Therapeutics, Inc. | Mehta Vimal92 | CEO, President, Secretary | Buy | 1,000 | $5.10 | $5,104.00 | +62.5% | |
| Nov 30, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 933 | $21.76 | $20,304.04 | -9.6% | |
| Nov 30, 2018 | LNTH Lantheus Holdings, Inc. | Orlandi Cesare | Chief Medical Officer | Sell | 7,055 | $18.01 | $127,075.16 | -2.0% | |
| Nov 29, 2018 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Buy | 500 | $5.02 | $2,511.15 | New | |
| Nov 29, 2018 | BTAI Bioxcel Therapeutics, Inc. | Steinhart Richard I87 | Chief Financial Officer | Buy | 500 | $5.00 | $2,500.00 | New | |
| Nov 29, 2018 | BTAI Bioxcel Therapeutics, Inc. | Nandabalan Krishnan75 | Director, 10% Owner | Buy | 1,000 | $4.92 | $4,915.00 | New | |
| Nov 29, 2018 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 5,000 | $20.50 | $102,500.00 | -12.4% | |
| Nov 29, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 185,000 | $117.42 | $21,722,428.80 | - | |
| Nov 29, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 258,128 | $4.96 | $1,280,324.35 | -8.1% | |
| Nov 28, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 190,000 | $115.57 | $21,957,939.00 | -0.2% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.